The response rate was found to be 26% in all patients and 22% in patients with pancreatic specifically.13 Another multicenter phase II study, RUCAPANC, enrolled patients with BRCA1 or BRCA2 mutations and pancreatic cancer. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.